134 related articles for article (PubMed ID: 23585021)
1. Tubulin-β-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones.
Roque DM; Bellone S; English DP; Buza N; Cocco E; Gasparrini S; Bortolomai I; Ratner E; Silasi DA; Azodi M; Rutherford TJ; Schwartz PE; Santin AD
Cancer; 2013 Jul; 119(14):2582-92. PubMed ID: 23585021
[TBL] [Abstract][Full Text] [Related]
2. Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas.
Osterberg L; Levan K; Partheen K; Delle U; Olsson B; Sundfeldt K; Horvath G
BMC Cancer; 2009 Oct; 9():368. PubMed ID: 19835627
[TBL] [Abstract][Full Text] [Related]
3. Novel microtubule-targeting agents - the epothilones.
Cheng KL; Bradley T; Budman DR
Biologics; 2008 Dec; 2(4):789-811. PubMed ID: 19707459
[TBL] [Abstract][Full Text] [Related]
4. Characterizing the Epothilone Binding Site on β-Tubulin by Photoaffinity Labeling: Identification of β-Tubulin Peptides TARGSQQY and TSRGSQQY as Targets of an Epothilone Photoprobe for Polymerized Tubulin.
Ranade AR; Higgins L; Markowski TW; Glaser N; Kashin D; Bai R; Hong KH; Hamel E; Höfle G; Georg GI
J Med Chem; 2016 Apr; 59(7):3499-514. PubMed ID: 26986898
[TBL] [Abstract][Full Text] [Related]
5. Targeting Galectin 3 illuminates its contributions to the pathology of uterine serous carcinoma.
Matoba Y; Zarrella DT; Pooladanda V; Azimi Mohammadabadi M; Kim E; Kumar S; Xu M; Qin X; Ray LJ; Devins KM; Kumar R; Kononenko A; Eisenhauer E; Veillard IE; Yamagami W; Hill SJ; Sarosiek KA; Yeku OO; Spriggs DR; Rueda BR
Br J Cancer; 2024 May; 130(9):1463-1476. PubMed ID: 38438589
[TBL] [Abstract][Full Text] [Related]
6. Ascites-Derived Organoids to Depict Platinum Resistance in Gynaecological Serous Carcinomas.
Arias-Diaz AE; Ferreiro-Pantin M; Barbazan J; Perez-Beliz E; Ruiz-Bañobre J; Casas-Arozamena C; Muinelo-Romay L; Lopez-Lopez R; Vilar A; Curiel T; Abal M
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686015
[TBL] [Abstract][Full Text] [Related]
7. Targeting Microtubule-Associated Protein Tau in Chemotherapy-Resistant Models of High-Grade Serous Ovarian Carcinoma.
Barbolina MV
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139693
[TBL] [Abstract][Full Text] [Related]
8. CCNE1 expression in high grade serous carcinoma does not correlate with chemoresistance.
Sapoznik S; Aviel-Ronen S; Bahar-Shany K; Zadok O; Levanon K
Oncotarget; 2017 Sep; 8(37):62240-62247. PubMed ID: 28977941
[TBL] [Abstract][Full Text] [Related]
9. Microtubule-Interfering Drugs: Current and Future Roles in Epithelial Ovarian Cancer Treatment.
Tymon-Rosario J; Adjei NN; Roque DM; Santin AD
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944858
[TBL] [Abstract][Full Text] [Related]
10. A novel SLC3A2-targeting antibody-drug conjugate exerts potent antitumor efficacy in head and neck squamous cell cancer.
Zheng M; Wang Z; Li M; Yang N; Lu H; Zhang Z; Dong Y; Chen Y; Zhu Z; Tong A; Yang H
Transl Oncol; 2024 May; 45():101981. PubMed ID: 38703658
[TBL] [Abstract][Full Text] [Related]
11. A review of basic to clinical targeted therapy and immunotherapy in uterine serous cancer.
Sun B; Zhao N; Cheng Y; Wang J
Mol Biol Rep; 2023 Aug; 50(8):6901-6912. PubMed ID: 37326746
[TBL] [Abstract][Full Text] [Related]
12. Endometrial carcinoma: association between mutational status, sites of metastasis, recurrence, and correlation with overall survival.
Luna C; Goncalves N; Metalonis SW; Mason MM; Lyu J; Huang M; Alessandrino F
Abdom Radiol (NY); 2023 Aug; 48(8):2684-2694. PubMed ID: 37289213
[TBL] [Abstract][Full Text] [Related]
13. In Silico Exploration of Microtubule Agent Griseofulvin and Its Derivatives Interactions with Different Human β-Tubulin Isotypes.
Aris P; Mohamadzadeh M; Kruglikov A; Askari Rad M; Xia X
Molecules; 2023 Mar; 28(5):. PubMed ID: 36903629
[TBL] [Abstract][Full Text] [Related]
14. Resistance to anti-tubulin agents: From vinca alkaloids to epothilones.
Krause W
Cancer Drug Resist; 2019; 2(1):82-106. PubMed ID: 35582143
[TBL] [Abstract][Full Text] [Related]
15. PI3K/AKT Signaling Tips the Balance of Cytoskeletal Forces for Cancer Progression.
Deng S; Leong HC; Datta A; Gopal V; Kumar AP; Yap CT
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406424
[TBL] [Abstract][Full Text] [Related]
16. Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.
Roque DM; Siegel ER; Buza N; Bellone S; Silasi DA; Huang GS; Andikyan V; Clark M; Azodi M; Schwartz PE; Rao GG; Reader JC; Hui P; Tymon-Rosario JR; Harold J; Mauricio D; Zeybek B; Menderes G; Altwerger G; Ratner E; Santin AD
Br J Cancer; 2022 Jun; 126(12):1695-1703. PubMed ID: 35149854
[TBL] [Abstract][Full Text] [Related]
17. Exosomal TUBB3 mRNA expression of metastatic castration-resistant prostate cancer patients: Association with patient outcome under abiraterone.
Zhu S; Ni Y; Sun G; Wang Z; Chen J; Zhang X; Zhao J; Zhu X; Dai J; Liu Z; Liang J; Zhang H; Zhang Y; Shen P; Zeng H
Cancer Med; 2021 Sep; 10(18):6282-6290. PubMed ID: 34318630
[TBL] [Abstract][Full Text] [Related]
18. Systems pharmacogenomics identifies novel targets and clinically actionable therapeutics for medulloblastoma.
Genovesi LA; Millar A; Tolson E; Singleton M; Hassall E; Kojic M; Brighi C; Girard E; Andradas C; Kuchibhotla M; Bhuva DD; Endersby R; Gottardo NG; Bernard A; Adolphe C; Olson JM; Taylor MD; Davis MJ; Wainwright BJ
Genome Med; 2021 Jun; 13(1):103. PubMed ID: 34154646
[TBL] [Abstract][Full Text] [Related]
19. A Compressive Review about Taxol
Gallego-Jara J; Lozano-Terol G; Sola-Martínez RA; Cánovas-Díaz M; de Diego Puente T
Molecules; 2020 Dec; 25(24):. PubMed ID: 33348838
[TBL] [Abstract][Full Text] [Related]
20. Intrinsic and Extrinsic Factors Affecting Microtubule Dynamics in Normal and Cancer Cells.
Borys F; Joachimiak E; Krawczyk H; Fabczak H
Molecules; 2020 Aug; 25(16):. PubMed ID: 32823874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
